Celladon Corporation – In December 2004, Targeted Genetics established a collaboration with Celladon Corporation focused on the development of AAV-based drugs for the treatment of congestive heart failure. In connection with the formation of this collaboration, Enterprise Partners and Venrock Associates purchased shares of our common stock for net proceeds of $6.0 million.
About Celladon – Celladon, Inc., a privately held company based in La Jolla, California, was founded by Dr. Kenneth R. Chien M.D., Ph.D. and Dr. Roger J. Hajjar, M.D. The company is focused on developing novel molecular therapies for congestive heart failure. The company’s first product targets the treatment of congestive heart failure by enhancing calcium cycling in the heart through a gene based therapy. Founding investors include Enterprise Partners Venture Capital and Venrock Associates. For more information about Celladon, visit its website at www.celladon.net.
MULTIPLE ACADEMIC PARTNERS
Targeted Genetics also maintains strong relationships with various academic institutions. Our capabilities enable us to license technologies that are interesting and applicable to our research, product development and manufacturing.
|
